NeuBase rises on positive data from muscular dystrophy treatment trial

NeuBase Therapeutics

16/12/2020 13:05

** Drug developer's shares  NBSE.O  rise 15.2% to $15.3
premarket 
    ** Co announces positive data for anti-gene therapies to
treat myotonic dystrophy type 1 (DM1) in preclinical study 
    ** DM1, a type of muscular dystrophy, is caused by a genetic
mutation in the DMPK gene, leading to mis-splicing of broad
spectrum of genes and DMPK protein insufficiency
    ** DMPK gene provides instructions for making a protein
called myotonic dystrophy protein
    ** NBSE says therapy candidate can rapidly resolve
mis-splicing without negatively impacting DMPK protein levels
 urn:newsml:reuters.com:*:nGNX7C6W3Z
    ** Co says it will provide additional updates on its
platform and pipeline of programs at an R&D day in H1 2021
    ** Up to Tuesday's close, stock rose 11.8% YTD

 (Reporting by Dania Nadeem in Bengaluru)
 ((Dania.Nadeem@thomsonreuters.com;))